Amendment No. 4 to Consulting Services Agreement between Vistagen Therapeutics, Inc. and FitzPatrick & Co. LLC
Vistagen Therapeutics, Inc. and FitzPatrick & Co. LLC have agreed to end their Consulting Services Agreement, originally dated January 21, 2022, and previously amended three times. This fourth amendment sets the agreement's expiration date as October 1, 2023. All other terms of the original agreement remain unchanged. Both parties have signed to confirm their acceptance of this amendment.
Exhibit 10.2
AMENDMENT NO. 4
TO
CONSULTING SERVICES AGREEMENT
This Amendment (“Amendment No. 4”) is made between Vistagen Therapeutics, Inc., a Nevada corporation having an address at 343 Allerton Avenue, South San Francisco, California 94080 (“Vistagen”), and FitzPatrick & Co. LLC, a Delaware limited liability company, having an address at 2023 Allen Place, NW, Washington DC 20009 (“Consultant”), and is effective as of October 1, 2023.
WHEREAS, Vistagen and Consultant entered into a Consulting Services Agreement dated January 21, 2022, as amended by Amendment No. 1 dated June 1, 2022, as amended by Amendment No. 2 dated January 1, 2023, and as amended by Amendment No. 3 dated July 1, 2023 (collectively, the “Agreement”); and
WHEREAS, the parties mutually wish to conclude the term of the Agreement.
Vistagen and Consultant, therefore, agree as follows:
AMENDMENT
1. The term of this Agreement shall expire on October 1, 2023.
Except as expressly provided in this Amendment No. 4, the terms of the Agreement remain unchanged.
Each party is signing this agreement with the party’s authorized signature.
| AGREED TO:
VISTAGEN THERAPEUTICS, INC.
| AGREED TO:
FITZPATRICK & CO., LLC | |||
| By: | /s/ Shawn K. Singh, J.D. | By: | /s/ Margaret Mary FitzPatrick | |
| Name: | Shawn K. Singh, J.D. | Name: | Margaret Mary FitzPatrick | |
| Title: | Chief Executive Officer | Title: | Chief Executive Officer | |
| Date: | November 9, 2023 | Date: | November 9, 2023 | |
Page 1
